A Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Patients Affected by Cystic Fibrosis and Non Cystic Fibrosis Bronchiectasis
Latest Information Update: 04 Nov 2021
At a glance
- Drugs CHF 6333 (Primary)
- Indications Bronchiectasis; Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chiesi Farmaceutici
Most Recent Events
- 29 Mar 2021 Status changed from recruiting to completed.
- 26 Jan 2021 Planned End Date changed from 1 Dec 2020 to 28 Feb 2021.
- 26 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 28 Feb 2021.